MSC vs exosomes for Autism Spectrum Disorder: what the registries show
For Autism Spectrum Disorder, the registry holds 10 MSC records against 5 exosomes records. MSC carries the larger research programme; neither column is a head-to-head efficacy result. Snapshot 2026-08-29.
Side by side
| Metric | MSC | exosomes |
|---|---|---|
| Registered studies | 10 | 5 |
| Recruiting now | 4 | 4 |
| Phase 3 or 4 records | 0 | 0 |
| Completed | 4 | 0 |
| Stopped early | 0 | 0 |
| Countries with sites | 6 | 4 |
| Median planned enrolment | 46 | 100 |
| First registration year | 2,009 | 2,024 |
The condition underneath the comparison
Autism is a neurodevelopmental difference, not a lesion to repair, and that framing gap sits under every commercial offer. Registered studies typically test whether immune modulation changes specific behavioural measures. Development itself produces change over months, which is why uncontrolled reports of improvement in children are the least informative data in this entire field.
MSC: what it is
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
exosomes: what it is
Exosome and extracellular-vesicle products are cell-free: vesicles harvested from cultured cells and given without the cells themselves. They are attractive commercially because they avoid live-cell logistics, and they are regulatorily contested for the same reason — several regulators have issued explicit warnings about unapproved exosome products marketed for human use.
Maturity difference
MSC has 0 Phase 3/4 records and 4 completed studies; exosomes has 0 and 0. Where both sit early on the ladder, the honest answer to "which works better" is that registrations cannot tell you.
Leading MSC studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07304440 — Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study | Phase 1, Phase 2 | Recruiting | 100 | Adia Med of Winter Park LLC | 2026-05-01 |
| NCT07243561 — Prospective Clinical Study on Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Childhood Autism | Phase 1, Phase 2 | Recruiting | 60 | Dongfang People's Hospital | 2025-09-01 |
| NCT07622316 — GAIP ASD Research Study | Phase 1 | Recruiting | 100 | Greater Atlanta Integrative Pediatrics | 2026-06-01 |
| NCT05003960 — Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism | Phase 1 | Recruiting | 15 | The Foundation for Orthopaedics and Regenerative Medicine | 2022-01-23 |
| NCT07546942 — Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Inte | Phase 1, Phase 2 | Enrolling By Invitation | 50 | Black Tie Medical, Inc. | 2026-04-30 |
Leading exosomes studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07304440 — Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study | Phase 1, Phase 2 | Recruiting | 100 | Adia Med of Winter Park LLC | 2026-05-01 |
| NCT07243561 — Prospective Clinical Study on Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Childhood Autism | Phase 1, Phase 2 | Recruiting | 60 | Dongfang People's Hospital | 2025-09-01 |
| NCT07622316 — GAIP ASD Research Study | Phase 1 | Recruiting | 100 | Greater Atlanta Integrative Pediatrics | 2026-06-01 |
| NCT06600529 — Combined Photo-Biomodulation At Acupuncture Points, Autologous PRP, and Umbilical Cord-Derived Exosome Therapy in Autism Spectrum Disorder | n/a | Recruiting | 100 | Iffat Anwar Medical Complex | 2024-08-13 |
| NCT07521384 — Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy | n/a | Enrolling By Invitation | 36 | Healing Hope International | 2026-06-01 |
The honest comparison
Head-to-head trials putting these two approaches in the same protocol are rare or absent for most conditions. Comparing counts from separate registry queries shows where research effort went — driven by cost, regulation and sponsor interest as much as by biology. Anyone presenting one column of this table as proof of superiority is overreading it.
Frequently asked
Is MSC better than exosomes for Autism Spectrum Disorder?
The registries cannot answer that. They show research volume and maturity, not comparative effectiveness: 10 vs 5 registered records (2026-08-29).
Which has more late-stage research for Autism Spectrum Disorder?
MSC: 0 Phase 3/4 records. exosomes: 0.
Can a clinic offer both?
Some do, which is itself worth questioning — a provider offering every modality for every condition is describing a business model, not a treatment rationale.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.